Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1-2
|
| pubmed:dateCreated |
1992-2-13
|
| pubmed:abstractText |
Calcium valproate is an anticonvulsant agent with pharmacokinetic properties similar to sodium valproate and valproic acid. Potential carcinogenesis of calcium valproate was evaluated in B6C3F1 mice and Wistar rats given 125, 250 and 500 mg/kg in the diet for 104 weeks. Survival in treated rats increased in a dose-related pattern despite a tumorigenic response in females. Adenocarcinomas of the uterus and cervix were increased in treated rats when compared to controls. The incidence of uterine neoplasia was 8, 20, 14 and 32% in the control, 125, 250 and 500 mg/kg groups, respectively. Neoplasia in treated rats were detected against a higher than expected background of adenocarcinomas in concurrent controls, since 8% incidence in controls was substantially above the laboratory historical database value of 0.6%. Tumors varied from epithelial masses confined to the endometrium, to transmural, highly desmoplastic neoplasms that invaded the serosa lining and the peritoneal cavity. These tumors metastasized in treated rats but not in controls. The statistically significant (P less than 0.01) increase in uterine adenocarcinomas found in females given 500 mg/kg of calcium valproate contrasts the absence of this tumor type in a previous rat carcinogenicity bioassay with valproic acid. Subcutaneous fibrosarcomas were significantly increased in valproic acid-treated males, but no uterine tumors were reported in females. It is puzzling that a true carcinogenic potential would be expressed by markedly different target organs as obtained with the acid and calcium salt of this moiety.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0300-483X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
71
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
35-47
|
| pubmed:dateRevised |
2003-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:1729766-Adenocarcinoma,
pubmed-meshheading:1729766-Administration, Oral,
pubmed-meshheading:1729766-Animals,
pubmed-meshheading:1729766-Body Weight,
pubmed-meshheading:1729766-Female,
pubmed-meshheading:1729766-Kidney Neoplasms,
pubmed-meshheading:1729766-Male,
pubmed-meshheading:1729766-Rats,
pubmed-meshheading:1729766-Rats, Inbred Strains,
pubmed-meshheading:1729766-Uterine Neoplasms,
pubmed-meshheading:1729766-Valproic Acid
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Calcium valproate-induced uterine adenocarcinomas in Wistar rats.
|
| pubmed:affiliation |
Department of Pathology and Experimental Toxicology, Parke-Davis Pharmaceutical Research Division, Ann Arbor, MI 48105.
|
| pubmed:publicationType |
Journal Article
|